Which has better valuation & earnings, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.68 $7.77B $0.70 42.03 Amgen $36.75B 6.89 $7.71B $17.24 27.15

Is PFE or AMGN more profitable?

Amgen has a net margin of 24.14% compared to Pfizer's net margin of 6.34%. Amgen's return on equity of 114.99% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.34% 19.88% 8.52% Amgen 24.14% 114.99% 13.47%

Does the media prefer PFE or AMGN?

In the previous week, Pfizer had 6 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Pfizer and 62 mentions for Amgen. Amgen's average media sentiment score of 0.71 beat Pfizer's score of 0.64 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 24 Very Positive mention(s) 8 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is GILD or PFE more profitable?

Pfizer has a net margin of 6.34% compared to Gilead Sciences' net margin of -12.47%. Pfizer's return on equity of 19.88% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -12.47% -1.85% -0.61% Pfizer 6.34% 19.88% 8.52%

Does the media prefer GILD or PFE?

In the previous week, Pfizer had 23 more articles in the media than Gilead Sciences. MarketBeat recorded 68 mentions for Pfizer and 45 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.68 beat Pfizer's score of 0.64 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 27 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation and earnings, PFE or MRNA?

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.68 $7.77B $0.70 42.03 Moderna $2.52B 39.93 -$2.82B -$7.10 N/A

Is PFE or MRNA more profitable?

Pfizer has a net margin of 6.34% compared to Moderna's net margin of -110.46%. Pfizer's return on equity of 19.88% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.34% 19.88% 8.52% Moderna -110.46% -25.79% -15.85%

Does the media refer more to PFE or MRNA?

In the previous week, Moderna had 14 more articles in the media than Pfizer. MarketBeat recorded 82 mentions for Moderna and 68 mentions for Pfizer. Pfizer's average media sentiment score of 0.64 beat Moderna's score of 0.64 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 30 Very Positive mention(s) 16 Positive mention(s) 19 Neutral mention(s) 2 Negative mention(s) 5 Very Negative mention(s) Positive

Which has better valuation and earnings, NVAX or PFE?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.47 $440.30M -$0.46 N/A Pfizer $62.58B 2.68 $7.77B $0.70 42.03

Is NVAX or PFE more profitable?

Pfizer has a net margin of 6.34% compared to Novavax's net margin of -18.64%. Pfizer's return on equity of 19.88% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -18.64% -14.82% -7.55% Pfizer 6.34% 19.88% 8.52%

Does the media favor NVAX or PFE?

In the previous week, Pfizer had 34 more articles in the media than Novavax. MarketBeat recorded 68 mentions for Pfizer and 34 mentions for Novavax. Pfizer's average media sentiment score of 0.64 beat Novavax's score of 0.36 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 10 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings and valuation, ABBV or PFE?

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 8.52 $4.23B $5.81 50.76 Pfizer $62.58B 2.68 $7.77B $0.70 42.03

Is ABBV or PFE more profitable?

AbbVie has a net margin of 15.67% compared to Pfizer's net margin of 6.34%. Pfizer's return on equity of 19.88% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 15.67% -450.55% 16.50% Pfizer 6.34% 19.88% 8.52%

Does the media prefer ABBV or PFE?

In the previous week, Pfizer had 16 more articles in the media than AbbVie. MarketBeat recorded 68 mentions for Pfizer and 52 mentions for AbbVie. AbbVie's average media sentiment score of 0.96 beat Pfizer's score of 0.64 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 38 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 30 Very Positive mention(s) 7 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Pfizer (PFE) Competitors

$29.42 +0.06 (+0.20%)

Closing price 11/11/2026 03:59 PM Eastern

Extended Trading

$29.47 +0.05 (+0.18%)

As of 11/11/2026 07:59 PM Eastern

Compare

PFE vs. AMGN, GILD, MRNA, NVAX, and ABBV

Should you buy Pfizer stock or one of its competitors? Pfizer's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Pfizer compare to Amgen?

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Pfizer currently has a consensus target price of $30.39, suggesting a potential upside of 3.30%. Amgen has a consensus target price of $422.76, suggesting a potential downside of 9.69%. Given Pfizer's higher probable upside, equities research analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19
Amgen	3 Sell rating(s)	18 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.30

Pfizer has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Amgen has a net margin of 24.14% compared to Pfizer's net margin of 6.34%. Amgen's return on equity of 114.99% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.34%	19.88%	8.52%
Amgen	24.14%	114.99%	13.47%

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 5.8%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.2%. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 58.5% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Amgen has increased its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03
Amgen	$36.75B	6.89	$7.71B	$17.24	27.15

In the previous week, Pfizer had 6 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Pfizer and 62 mentions for Amgen. Amgen's average media sentiment score of 0.71 beat Pfizer's score of 0.64 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	24 Very Positive mention(s)	8 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Amgen beats Pfizer on 14 of the 20 factors compared between the two stocks.

How does Pfizer compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Gilead Sciences has higher earnings, but lower revenue than Pfizer. Gilead Sciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	7.15	$8.51B	-$3.16	N/A
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03

Gilead Sciences has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Pfizer had 23 more articles in the media than Gilead Sciences. MarketBeat recorded 68 mentions for Pfizer and 45 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.68 beat Pfizer's score of 0.64 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	27 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 1.9%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 5.8%. Gilead Sciences pays out -103.8% of its earnings in the form of a dividend. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer has a net margin of 6.34% compared to Gilead Sciences' net margin of -12.47%. Pfizer's return on equity of 19.88% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-12.47%	-1.85%	-0.61%
Pfizer	6.34%	19.88%	8.52%

Gilead Sciences currently has a consensus price target of $170.15, indicating a potential upside of 0.25%. Pfizer has a consensus price target of $30.39, indicating a potential upside of 3.30%. Given Pfizer's higher possible upside, analysts clearly believe Pfizer is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

Pfizer beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.

How does Pfizer compare to Moderna?

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Pfizer has a net margin of 6.34% compared to Moderna's net margin of -110.46%. Pfizer's return on equity of 19.88% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.34%	19.88%	8.52%
Moderna	-110.46%	-25.79%	-15.85%

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03
Moderna	$2.52B	39.93	-$2.82B	-$7.10	N/A

Pfizer has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Moderna has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Pfizer currently has a consensus target price of $30.39, suggesting a potential upside of 3.30%. Moderna has a consensus target price of $113.75, suggesting a potential downside of 54.26%. Given Pfizer's stronger consensus rating and higher probable upside, equities research analysts plainly believe Pfizer is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19
Moderna	4 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Moderna had 14 more articles in the media than Pfizer. MarketBeat recorded 82 mentions for Moderna and 68 mentions for Pfizer. Pfizer's average media sentiment score of 0.64 beat Moderna's score of 0.64 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	30 Very Positive mention(s)	16 Positive mention(s)	19 Neutral mention(s)	2 Negative mention(s)	5 Very Negative mention(s)	Positive

68.4% of Pfizer shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pfizer beats Moderna on 10 of the 15 factors compared between the two stocks.

How does Pfizer compare to Novavax?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Novavax presently has a consensus price target of $12.33, indicating a potential upside of 23.58%. Pfizer has a consensus price target of $30.39, indicating a potential upside of 3.30%. Given Novavax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19

Novavax has a beta of 2.65, indicating that its share price is 165% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Pfizer has a net margin of 6.34% compared to Novavax's net margin of -18.64%. Pfizer's return on equity of 19.88% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-18.64%	-14.82%	-7.55%
Pfizer	6.34%	19.88%	8.52%

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.47	$440.30M	-$0.46	N/A
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03

53.0% of Novavax shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pfizer had 34 more articles in the media than Novavax. MarketBeat recorded 68 mentions for Pfizer and 34 mentions for Novavax. Pfizer's average media sentiment score of 0.64 beat Novavax's score of 0.36 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	10 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Pfizer beats Novavax on 11 of the 15 factors compared between the two stocks.

How does Pfizer compare to AbbVie?

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.76
Pfizer	$62.58B	2.68	$7.77B	$0.70	42.03

AbbVie has a net margin of 15.67% compared to Pfizer's net margin of 6.34%. Pfizer's return on equity of 19.88% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	15.67%	-450.55%	16.50%
Pfizer	6.34%	19.88%	8.52%

70.2% of AbbVie shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.3%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 5.8%. AbbVie pays out 119.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years and Pfizer has increased its dividend for 16 consecutive years.

AbbVie presently has a consensus target price of $297.46, indicating a potential upside of 0.86%. Pfizer has a consensus target price of $30.39, indicating a potential upside of 3.30%. Given Pfizer's higher possible upside, analysts clearly believe Pfizer is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pfizer	2 Sell rating(s)	13 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.19

In the previous week, Pfizer had 16 more articles in the media than AbbVie. MarketBeat recorded 68 mentions for Pfizer and 52 mentions for AbbVie. AbbVie's average media sentiment score of 0.96 beat Pfizer's score of 0.64 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	38 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	30 Very Positive mention(s)	7 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

AbbVie beats Pfizer on 12 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFE vs. The Competition

Export

Metric	Pfizer	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$167.35B	$13.80B	$7.89B	$23.43B
Dividend Yield	5.86%	2.55%	2.45%	3.74%
P/E Ratio	9.63	25.97	34.27	25.45
Price / Sales	2.68	8.18	8.78	3.23
Price / Cash	6.68	15.68	22.08	15.86
Price / Book	1.88	5.04	4.45	3.73
Net Income	$7.77B	$2.87B	$3.50B	$1.08B
7 Day Performance	-1.64%	2.87%	2.56%	2.53%
1 Month Performance	3.62%	-4.50%	-3.18%	1.23%
1 Year Performance	13.84%	-6.34%	1.04%	6.57%

Pfizer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFE Pfizer	3.6516 of 5 stars	$29.42 +0.2%	$30.39 +3.3%	+15.4%	$167.35B	$62.58B	9.63	75,000	Trending News Analyst Upgrade
AMGN Amgen	4.4461 of 5 stars	$465.45 -0.1%	$389.71 -16.3%	+38.3%	$244.27B	$36.75B	20.20	31,500	Trending News
GILD Gilead Sciences	3.3069 of 5 stars	$170.33 -0.2%	$169.74 -0.3%	+38.5%	$197.40B	$29.44B	N/A	17,000	Trending News Insider Trade
MRNA Moderna	1.7062 of 5 stars	$220.83 -0.4%	$107.10 -51.5%	+841.7%	$85.50B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Forecast Analyst Revision
NVAX Novavax	2.0417 of 5 stars	$9.53 -5.5%	$12.33 +29.4%	+34.1%	$1.70B	$1.12B	N/A	749	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PFE) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Competitors